Shares of Icon Plc (NASDAQ:ICLR) have received a consensus rating of “Buy” from the twelve ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $156.14.
ICLR has been the topic of several recent research reports. Zacks Investment Research upgraded shares of HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd. ValuEngine upgraded shares of Yirendai from a “strong sell” rating to a “sell” rating in a research report on Friday, May 3rd. Mizuho lifted their price objective on shares of Icon from $154.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, June 11th. Wolfe Research initiated coverage on shares of Iqvia in a research report on Tuesday, April 2nd. They issued a “market perform” rating on the stock. Finally, BidaskClub downgraded shares of Amyris from a “hold” rating to a “sell” rating in a research report on Thursday, June 27th.
NASDAQ:ICLR traded up $1.95 during mid-day trading on Friday, hitting $152.64. The stock had a trading volume of 223,204 shares, compared to its average volume of 282,637. The stock has a market capitalization of $8.10 billion, a PE ratio of 23.99, a price-to-earnings-growth ratio of 2.06 and a beta of 0.56. The stock’s 50 day moving average is $147.69. Icon has a 52 week low of $118.10 and a 52 week high of $156.34. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.02 and a quick ratio of 2.02.
A number of institutional investors have recently added to or reduced their stakes in the business. Clearbridge Investments LLC increased its stake in Icon by 5.9% during the 1st quarter. Clearbridge Investments LLC now owns 2,353,035 shares of the medical research company’s stock valued at $321,378,000 after buying an additional 130,954 shares during the period. Boston Partners grew its stake in shares of Icon by 9.1% in the 1st quarter. Boston Partners now owns 1,503,804 shares of the medical research company’s stock worth $205,390,000 after purchasing an additional 125,498 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Icon by 1.1% in the 1st quarter. Principal Financial Group Inc. now owns 1,063,822 shares of the medical research company’s stock worth $145,296,000 after purchasing an additional 11,178 shares during the last quarter. Norges Bank acquired a new position in shares of Icon in the 4th quarter worth approximately $84,127,000. Finally, Comgest Global Investors S.A.S. grew its stake in shares of Icon by 47.4% in the 1st quarter. Comgest Global Investors S.A.S. now owns 484,053 shares of the medical research company’s stock worth $66,112,000 after purchasing an additional 155,720 shares during the last quarter. 85.74% of the stock is currently owned by hedge funds and other institutional investors.
Icon Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Further Reading: Technical Indicators – What is a Golden Cross?
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.